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Georgeta Fried*† and Mor Moskovitz†Abstract
This retrospective study evaluated the impact of intermediate Recurrence ScoreW results on adjuvant treatment decisions
in estrogen receptor-positive (ER+) early invasive breast cancer, comparing treatment recommendations pre-testing
with actual treatments received post-testing. Of the 111 patients included in the analysis, 78 (70.3%) had hormonal
therapy (HT) and 33 (29.7%) had chemohormonal therapy (CHT) recommendations pre-testing. The Recurrence Score
was significantly higher in those with a pre-testing CHT recommendation compared with those with a pre-testing HT
recommendation (median of 24 vs. 22; P = 0.047; Mann–Whitney–Wilcoxon [MWW] test). Post-testing, treatment of 24
patients (21.6%) was different from their pre-testing recommendation. The difference between CHT recommendation
rate pre-testing and the rate of CHT received post-testing was nonsignificant for the entire cohort and for patients’
subgroups (by age, tumor size, and grade) (P >0.17; McNemar’s test). Following classification of the cohort into two
Recurrence Score subcategories (low-intermediate, [18-25]; high-intermediate, [26-30]), changes in treatment decisions
(pre-testing recommendations vs. actual treatments received post testing) were reported for 16.5% of low-intermediate
and 34.4% of high-intermediate patients. Post-testing, the rate of CHT decreased (by 58%) in the low-intermediate
subcategory and increased (by 64%) in the high-intermediate subcategory (P <0.01, both subcategories). In logistic
regression analyses, the Recurrence Score subcategory was the only significant predictor of changes in treatment
decisions (pre-testing recommendations vs. actual treatments received post testing; P <0.01). The only significant
difference between the two subsets of patients with such a change (HT to CHT, 11 patients; CHT to HT, 13 patients)
was the Recurrence Score (median of 28 vs. 20, respectively; P = 0.0014; MWW test). These findings demonstrate that
intermediate Recurrence Score results provide clinically relevant information and impact treatment decisions in ER + early
breast cancer.
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The Oncotype DXW Breast Cancer assay (Genomic
Health, Inc., Redwood City, CA) has been validated as
a prognosticator and a predictor of the likelihood of
chemotherapy benefit in estrogen receptor-positive (ER+)
early invasive breast cancer (Paik et al. 2004; Paik et al.
2006; Habel et al. 2006; Goldstein et al. 2008; Albain et al.
2010; Dowsett et al. 2010; Toi et al. 2010; Mamounas
et al. 2012). The Oncotype DX Recurrence ScoreW is a con-
tinuous value ranging from 0 to 100; it can be used to clas-
sify patients into 3 risk categories: low (<18), intermediate* Correspondence: g_fried@rambam.health.gov.il
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reproduction in any medium, provided the orig(18-30), and high (≥31) (Paik et al. 2004). For patients with
high Recurrence Score results, the benefit from adjuvant
chemotherapy is significant while for patients with low
Recurrence Score results, there is minimal, if any, benefit
from chemotherapy (Paik et al. 2006; Albain et al. 2010).
In the intermediate Recurrence Score category, adjuvant
chemotherapy may confer a modest benefit for some
patients (Paik et al. 2006; Albain et al. 2010). Since be-
coming available in 2004, numerous studies conducted
around the world (United States, European countries,
Japan, Australia, and Israel) have investigated its impact
on treatment decision-making in clinical practice and
have consistently shown that testing results in a change
in treatment recommendations in 19-51% of cases (fromThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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vice versa) correlating with a net reduction in chemother-
apy use (Oratz et al. 2007; Asad et al. 2008; Rayhanabad
et al. 2008; Henry et al. 2009; Klang et al. 2010; Lo et al.
2010; Ademuyiwa et al. 2011; de Boer et al. 2011; Geffen
et al. 2011; Kamal et al. 2011; Oratz et al. 2011; Yamauchi
et al. 2011; Albanell et al. 2012; Eiermann et al. 2012;
Gligorov et al. 2012; Albanell et al. 2013; Holt et al. 2013).
In the low Recurrence Score category (the largest cat-
egory including 40-58% of patients in these studies),
the recommendation change was mostly from chemo-
hormonal therapy to hormonal therapy alone and in
the high Recurrence Score category (the smallest cat-
egory including 5-21% of patients in these studies), the
recommendation change was mostly from hormonal
therapy to chemohormonal therapy (Oratz et al. 2007;
Klang et al. 2010; Lo et al. 2010; Ademuyiwa et al.
2011; Geffen et al. 2011; Oratz et al. 2011; Albanell
et al. 2012; Eiermann et al. 2012; Gligorov et al. 2012;
Albanell et al. 2013; Holt et al. 2013). In the inter-
mediate Recurrence Score category, the observed changes
in treatment recommendations were not consistent across
studies, and data on the impact of the Recurrence Score
and clinicopathologic characteristics on treatment recom-
mendations in this subpopulation are limited (Oratz et al.
2007; Klang et al. 2010; Lo et al. 2010; Ademuyiwa
et al. 2011; Geffen et al. 2011; Oratz et al. 2011; Albanell
et al. 2012; Eiermann et al. 2012; Gligorov et al. 2012;
Albanell et al. 2013; Holt et al. 2013). The current
study was designed to evaluate the associations be-
tween Recurrence Score results and clinicopathologic
characteristics in a cohort of patients with ER + early in-
vasive breast cancer and an intermediate Recurrence
Score result and to evaluate the impact of the Recurrence
Score results and clinicopathologic characteristics on treat-
ment decisions.
Materials and methods
Study design and patients
This retrospective single-institution cohort study involv-
ing patients with ER + early invasive breast cancer and
an intermediate Recurrence Score result included all
female patients who were diagnosed and treated in the
Rambam Health Care Campus (Haifa, Israel) between
October 2005 and September 2010. The study was
approved by the institutional review board of Rambam
Health Care Campus.
Data source
Clinicopathological characteristics, Recurrence Score
results, and treatments received were obtained from
patients’ records. Physicians’ treatment recommenda-
tions prior to Oncotype DX testing were documented on
requisition of the assay.Statistical analyses
Descriptive statistics were used to summarize clinicopatho-
logic characteristics and Recurrence Score results. T-test/
Mann–Whitney–Wilcoxon (MWW) and Chi-squared/
Fisher’s exact tests were used, as appropriate, to compare
continuous and categorical parameters, respectively, be-
tween patients treated with hormonal therapy alone and
those treated with chemohormonal therapy. McNemar's
test was used to assess whether the difference between
the proportions of patients with hormonal and chemo-
hormonal therapy recommendations (pre-testing) and
the proportion of patients who received hormonal and
chemohormonal therapy (post-testing) was significant.
Logistic regression analyses were used to assess the prob-
ability of a treatment change from pre-testing hormonal
therapy recommendation to post-testing treatment with
chemohormonal therapy and from pre-testing hormonal
therapy recommendation to post-testing treatment with
chemohormonal therapy as a function of patient’s age,
tumor size, tumor grade, and the Recurrence Score result.
All analyses were conducted using SAS statistical software
version 9. 2 (SAS Institute Inc., Cary, NC); P <0.05 was
considered significant.
Results
Patient and tumor characteristics
A total of 116 patients with intermediate Recurrence
Score results were included in the analysis (Table 1). Pa-
tients were followed for a median (range) of 30 (4-70)
months. The majority of patients (86.1%) were node
negative. Grade distribution was similar to that observed
in the general patient population undergoing Oncotype
DX testing in Israel (Ben-Baruch et al. 2013). Patients’
Recurrence Score results spanned the entire intermediate
Recurrence Score category (18-30) and the median Recur-
rence Score result was 22 (Table 1).
Clinicopathologic characteristics and Recurrence Score
results by pre-testing treatment recommendations
The analysis included 111 patients for whom informa-
tion about treatment recommendations before Oncotype
DX testing and actual treatments received was available.
Before testing, 78 patients (70.3%) were recommended
hormonal therapy alone and 33 patients (29.7%) were rec-
ommended chemohormonal therapy. These two groups
were not statistically significantly different with respect to
age (P = 0.056; t-test), and had statistically significant dif-
ferences with respect to tumor size (P = 0.0037, t-test),
nodal involvement (P = 0.00013, Fisher’s exact test), grade
distribution (P = 0.043, Chi-squared test), and surgery type
(lumpectomy vs. mastectomy, P = 0.0015, Chi-squared
test). In comparison to patients with a pre-testing recom-
mendation of hormonal therapy alone, those with a pre-
testing recommendation of chemohormonal therapy had




Mean (SD), years 56.2 (9.0)
Median (range), years 56.5 (35-76)
Tumor sizea
Mean (SD), mm 16.4 (6.9)
Median (range), mm 15.0 (6-55)
Nodal status,b n (%)
Node negative 93 (86.1)
Node positive 15 (13.9)








Mean (SD) 22.9 (3.7)
Median (range) 22 (18-30)
SD standard deviation.
aTumor size information was unavailable for 1 patient.
bNodal status information was unavailable for 8 patients.
cTumor grade information was unavailable for 12 patients.
dSurgery type information was unavailable for 1 patient.
Table 2 Baseline patient and tumor characteristics for
patients with pre-testing recommendations of hormonal








Mean (SD), years 57.4 (9.0) 53.8 (9.1)
Median (range), years 57.5 (37-76) 55 (35-72)
Tumor sizeb
Mean (SD), mm 14.8 (5.4) 20.1 (9.1)
Median (range), mm 14 (6-35) 19 (8.5-55)
Nodal status,c n (%)
Node negative 71 (94.7) 19 (63.3)
Node positive 4 (5.3) 11 (36.7)
Tumor grade,d n (%)
1 14 (20.6) 1 (3.2)
2 42 (61.8) 20 (64.5)
3 12 (17.7) 10 (32.3)
Type of surgery,e n (%)
Lumpectomy 71 (91.0) 22 (66.7)
Mastectomy 7 (9.0) 11 (33.3)
Recurrence score
resultf
Mean (SD) 22.5 (3.5) 24.1 (4.0)
Median (range) 22 (18-29) 24 (18-30)
SD standard deviation.
aP = 0.056 (t-test for comparing means).
bP = 0.0037 (t-test for comparing means). Tumor size information was
unavailable for 1 patient in the chemohormonal therapy group.
cP = 0.00013 (Fisher’s exact test). Nodal status information was unavailable for
3 patients in the hormonal therapy group and 3 patients in the
chemohormonal therapy group.
dP = 0.043 (Chi-squared test). Grade information was unavailable for 10
patients in the hormonal therapy group and 2 patients in the chemohormonal
therapy group.
eP = 0.0015 (Chi-squared test).
fP = 0.047 (MWW test).
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positive patients, grade 3 tumors, and patients who had
undergone mastectomy (Table 2).
Notably, the group with a pre-testing chemohormonal
therapy recommendation had a statistically significantly
higher median Recurrence Score result than the group
with a pre-testing hormonal therapy recommendation
(24 vs. 22; P = 0.047; MWW test) (Table 2).
Recurrence Score results and treatments received
After knowing the Recurrence Score results, 24 patients
(21.6%; 95% confidence interval [CI], 13.8-29.4%) re-
ceived treatment that was different from their pre-
testing treatment recommendation. Of the 78 patients
who were originally recommended hormonal therapy
alone, 11 received chemohormonal therapy (14.1%; 95%
CI, 6.2-22.0%); of the 33 patients who were originally
recommended chemohormonal therapy, 13 received
hormonal therapy alone (39.4%; 95% CI, 21.8-57.0%)
(Figure 1). Overall, there was virtually no difference be-
tween the proportion of patients who were recom-
mended chemohormonal therapy pre-testing and the
proportion of patients who received chemohormonaltherapy post-testing (29.7% before vs. 27.9% after; P = 0.68;
McNemar's test).
Treatment changes were also analyzed by age
(≤50, >50 years), tumor size (≤15 mm, >15 mm), and
grade (for patients with grade 2 and 3 tumors). In all the
analyzed subgroups, the net change in chemotherapy use
(i.e., the difference between the proportion of patients
with pre-testing chemohormonal therapy recommen-
dations and the proportion of patients who received
chemohormonal therapy post-testing) was nonsignificant
(P values between 0.18 and 0.82; McNemar's test). The
overall change rate in treatment decisions (from pre-
testing chemohormonal therapy recommendation to post-
testing hormonal therapy treatment and from pre-testing
Figure 1 Overall impact of knowing the Recurrence Score result on treatments received (n = 111). CHT chemohormonal therapy;
HT hormonal therapy.
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mohormonal therapy treatment) was similar in the
younger (≤50 years) and older (>50 years) age sub-
groups (16.7% [95% CI, 2.5-30.8%] vs. 23.5% [95% CI,
14.0-32.9%]), and in patients with smaller (≤15 mm)
and larger (>15 mm) tumors (16.9% [95% CI, 7.6-26.3%]
vs. 26.7% [95% CI, 13.2-40.1%]). Of the 16 patients with
grade 1 tumors, only 1 (6.3% [95% CI, 0-30.3%]) had a
treatment decision change (from pre-testing hormonal
therapy recommendation to receiving chemohormonal
therapy post-testing); in patients with grade 2 and grade 3
tumors, the overall change rate was more pronounced and
similar (24.2% [95% CI, 13.2-35.2%] and 27.3% [95% CI,
7.1-47.5%], respectively).
To explore whether clinicians perceive intermediate Re-
currence Score patients in a uniform manner, the cohort
was divided into two intermediate Recurrence Score sub-
categories (the low-intermediate subcategory [Recurrence
Score results: 18-25] and the high-intermediate subcat-
egory [Recurrence Score results: 26-30]; 25 was used as
the cutoff to define the subcategories as it is the cutoff
used in the ongoing Oncotype DX phase 3 TAILORx
and RxPONDER trials (ClinicalTrials.gov website 2013a;
ClinicalTrials.gov website 2013b)), and changes between
pre-testing treatment recommendations and post-testing
actual treatments received were analyzed for each subcat-
egory separately (Figure 2). Of the 79 patients with low-
intermediate Recurrence Score results, 13 (16.5% [95% CI,
8.3-24.7%]) had a change while 11 (34.4% [95% CI,
17.9-50.9%]) of the 32 patients with high-intermediate
Recurrence Score results had a change. Notably, in
the low-intermediate-Recurrence Score subcategory, the
changes were primarily from pre-testing chemohormonal
therapy recommendation to post-testing treatment with
hormonal therapy alone, and consequently, the overall
rate of chemohormonal therapy decreased significantly
after knowing the Recurrence Score results (by 58%, from
24.1% to 10.1%; P = 0.002; McNemar’s test). In the high-
intermediate-Recurrence Score subcategory, the changes
were primarily in the opposite direction (from hormonal to
chemohormonal therapy), and consequently, the overallrate of chemohormonal therapy increased significantly
after knowing the Recurrence Score results (by 64%, from
43.8% to 71.9%; P = 0.007; McNemar’s test).
To assess the impact of the clinicopathologic parame-
ters and the Recurrence Score results on treatment
changes, we modeled the probability of a change be-
tween treatment recommendation and actual treatment
received as a function of age (≤50, >50 years), tumor
size (≤15 mm, >15 mm), grade (1, 2, and 3), and the
Recurrence Score subcategory (low-intermediate and
high-intermediate, as defined above) for patients with
pre-testing hormonal therapy recommendations and for
patients with pre-testing chemohormonal therapy recom-
mendations. Possible interaction between the effect of the
Recurrence Score subcategory and patients’ age, tumor
size, or tumor grade (each separately) on the probability of
a treatment change was examined by the Breslow Day test.
As the effect of the Recurrence Score subcategory was
consistent in all subgroups (with the exception of one
small subgroup [n = 14]), and the Breslow Day tests were
nonsignificant (P >0.25), only main effects were consid-
ered for the logistic regression analyses. For patients with
a pre-testing hormonal therapy recommendation, the only
significant predictor of a treatment change was high-
intermediate Recurrence Score subcategory (odds ratio
[OR], 73.8 [95% CI, 8.3-655.2] vs. the low-intermediate
subcategory; P = 0.0001). For patients with a pre-testing
chemohormonal therapy recommendation, multivariate
logistic regression analysis was not technically possible
because there were only 33 such patients. For these
patients, univariate analysis was performed and demon-
strated that the low-intermediate Recurrence Score subcat-
egory was a significant predictor of a treatment change
(OR, 22.3 [95% CI, 2.4-208.8] vs. the high-intermediate
subcategory; P = 0.007).
Evaluation of the two subsets of patients with a treat-
ment change (11 patients with a pre-testing hormonal
therapy recommendation who were treated with chemo-
hormonal therapy post-testing, and 13 patients with a
pre-testing chemohormonal therapy recommendation
who were treated with hormonal therapy post-testing)
Figure 2 Impact of knowing the Recurrence Score result on treatments received in the low-intermediate Recurrence Score subcategory
(Recurrence Score values of 18-25; n = 79) (a) and in the high-intermediate Recurrence Score subcategory (Recurrence Score values of
26-30; n = 32) (b) CHT chemohormonal therapy; HT hormonal therapy.
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icopathologic parameters including patients’ age, tumor
size, nodal status, tumor grade, and type of surgery per-
formed between the groups (although the small sample
size limited our ability to draw conclusions) (Table 3).
Statistically significant differences between the groups
were noted with respect to Recurrence Score results
with higher Recurrence Score results in patients with
hormonal to chemohormonal therapy change than in
patients with the reverse change (median [range] of 28
[23-29] and 20 [18-28], respectively; P = 0.0014; MWW
test) (Table 3).
Discussion
Oncotype DX testing is routinely used in clinical practice
in Israel to support clinical decision making for patients
with ER + early invasive breast cancer. The current ana-
lysis focused on the impact of intermediate Recurrence
Score results on adjuvant treatment decisions in ER +
early invasive breast cancer in real-life clinical practice
and demonstrated that intermediate results led to a
change between pre-testing recommendations and actual
treatments received in approximately one-fifth (21.6%)
of the cohort. The observed changes were in both direc-
tions (from hormonal therapy alone to chemohormonal
therapy and vice versa) with no significant net change in
chemotherapy use (30% recommended pre-testing vs.
28% actually used). Unlike low- and high-Recurrence
Score patients, for whom the impact of the RecurrenceScore results on treatment decisions has been shown to
be consistent across studies (increased and decreased
chemotherapy use, respectively) (Oratz et al. 2007; Klang
et al. 2010; Lo et al. 2010; Ademuyiwa et al. 2011; Geffen
et al. 2011; Oratz et al. 2011; Albanell et al. 2012;
Eiermann et al. 2012; Gligorov et al. 2012; Albanell et al.
2013; Holt et al. 2013), in intermediate-Recurrence Score
patients, the overall impact of the Recurrence Score re-
sults on chemotherapy use is not consistent across stud-
ies and the overall net change ranged from an increased
use of chemotherapy by more than 85% to a decreased
use of chemotherapy by more than 40% (Oratz et al.
2007; Klang et al. 2010; Lo et al. 2010; Ademuyiwa
et al. 2011; Geffen et al. 2011; Oratz et al. 2011; Albanell
et al. 2012; Eiermann et al. 2012; Gligorov et al. 2012;
Albanell et al. 2013; Holt et al. 2013 ). These results are
consistent with the hypothesis that clinicians weigh add-
itional factors (e.g., the exact Recurrence Score value
and not the Recurrence Score category, age, grade, nodal
status, etc.) in considering chemotherapy for intermediate-
Recurrence Score patients.
Our study evaluated the factors that may influence
changes in treatment decisions in intermediate-Recurrence
Score patients. Traditional parameters such as patient’s
age, tumor size, and tumor grade, did not have a statisti-
cally significant impact on the change in chemotherapy
use from pre- to post-Oncotype DX testing. Notably,
the Recurrence Score itself did have a significant impact.
In patients who had a treatment change (pre-testing
Table 3 Clinicopathologic and Recurrence Score results in
patients with a treatment change (n = 24)





(n = 11) (n = 13)
Agea
Mean (SD), years 54.2 (3.4) 55.1 (9.5)
Median (range), years 54 (46-58) 56 (35-72)
Tumor size b
Mean (SD), mm 15.6 (5.7) 20.4 (7.6)
Median (range), mm 14 (10-28) 20.5 (10-32)
Nodal status,c n (%)
Node negative 10 (100) 8 (72.7)
Node positive 0 (0) 3 (27.3)
Tumor grade,d n (%)
1 1 (9.1) 0 (0)
2 8 (72.7) 7 (63.6)
3 2 (18.2) 4 (36.4)
Type of surgery,e n (%)
Lumpectomy 10 (90.9) 9 (69.2)
Mastectomy 1 (9.1) 4 (30.8)
Recurrence Score resultf
Mean (SD) 27.3 (1.7) 21.1 (3.0)
Median (range) 28 (23-29) 20 (18-28)
CHT chemohormonal therapy; HT hormonal therapy; SD standard deviation.
aP = 0.76 (t-test for comparing means).
bP = 0.11 (t-test for comparing means). Tumor size information was unavailable
for 1 patient in the chemohormonal to hormonal therapy group.
cP = 0.21 (Fisher’s exact test). Nodal status information was unavailable for 1
patient in the hormonal therapy to chemohormonal therapy group and 2
patients in the chemohormonal to hormonal therapy group.
dP = 0.64 (Fisher’s exact test). Grade information was unavailable for 2 patients
in the chemohormonal to hormonal therapy group.
eP = 0.33 (Fisher’s exact test).
fP = 0.0014 (MWW test).
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intermediate Recurrence Score results were significantly
associated with a decision to treat with chemohor-
monal therapy, suggesting that clinicians evaluate the
Recurrence Score as a continuous parameter and do not
consider all intermediate-Recurrence Score patients as
having the same risk of recurrence. Also, in an analysis
of treatment change by Recurrence Score subcategory
(using a cutoff of 25, which is the cutoff used in the on-
going Oncotype DX phase 3 TAILORx and RxPONDER
trials that were designed to assess chemotherapy benefit
in node-negative patients with Recurrence Score results
between 12 and 25 and node-positive patients with re-
sults ≤25, respectively (ClinicalTrials.gov website 2013a;
ClinicalTrials.gov website 2013b)), the treatment changes
were statistically significant with a decrease in chemo-
therapy use in the low-intermediate subcategory (58%relative decrease) and an increase in chemotherapy
use in the high-intermediate subcategory (64% relative
increase). This novel finding was also supported by a
logistic regression analysis demonstrating the statistical
significance of the Recurrence Score subcategory as a
predictor of a treatment change.
Oncotype DX testing has been shown to increase clini-
cians’ confidence in their treatment decisions (Lo et al.
2010; Albanell et al. 2012; Eiermann et al. 2012); only
one study analyzed this increase by patients’ Recurrence
Score results, and demonstrated that a higher proportion
of clinicians reported increased confidence when the
patients had low or high Recurrence Score results than
when the patients had intermediate Recurrence Score
results (Eiermann et al. 2012). In addition, several studies
have recently shown that patients experienced signifi-
cantly lower conflict about their treatment decisions
and decreased situational anxiety after receiving their
Recurrence Score results (Lo et al. 2010; In et al. 2011;
Eiermann et al. 2012). Only one study evaluated the im-
pact of intermediate Recurrence Score results on patients
and found that among patients who preferred a passive
role in their care (but not among those who preferred an
active/shared role), those with intermediate Recurrence
Score results had higher cancer-related distress than
patients with low/high Recurrence Score (Sulayman et al.
2012), possibly reflecting the uncertainty associated
with the potential benefit of chemotherapy in these
patients. Thus, it may be of interest to assess the impact of
intermediate Recurrence Score results (as a continuous
parameter) on clinicians’ confidence as well as on patients’
psychosocial status.
The limitations of this study include its retrospective
design and a relatively small sample size. In addition,
since this was a single-center study, its ability to repre-
sent treatment patterns in the general breast cancer
patient population in Israel may be limited.
In summary, our findings demonstrate that intermediate
Recurrence Score results are not perceived in a uniform
manner by clinicians, but rather provide clinically relevant
information that impacts adjuvant treatment decision-
making in patients with ER + early invasive breast cancer.
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